Skip to main content
Premium Trial:

Request an Annual Quote

NantHealth Receives Nasdaq Delisting Notice

NEW YORK (GenomeWeb) – NantHealth disclosed Friday after the close of the market that it has received a delisting notice from the Nasdaq Stock Market because its stock price has been below $1 for at least 30 consecutive business days.

The company disclosed this news in a filing with the Securities and Exchange Commission just ahead of the long holiday weekend in the US, though NantHealth said it received the delisting notice two days earlier.

Per Nasdaq rules, Culver City, California-based NantHealth has until July 15 to get its closing stock price to at least $1 for 10 consecutive business days to avoid delisting.

NantHealth shares closed the week at $.70. The company, the IT and precision medicine arm of Patrick Soon-Shiong's NantWorks empire, went public in 2015 at $14 per share.

For the quarter ended Sept. 30, NantHealth reported a net loss of $97.5 million, despite higher year-over-year revenues. The firm has never been profitable.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.